We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Membrane-Bound Enzyme Linked to Plaque Formation in Mouse Atherosclerosis Model

By LabMedica International staff writers
Posted on 21 Jul 2015
Image: Results presented in this study suggest that the enzyme CD39 can suppress the plaque buildup that may trigger heart attack or stroke (Photo courtesy of the University of Michigan).
Image: Results presented in this study suggest that the enzyme CD39 can suppress the plaque buildup that may trigger heart attack or stroke (Photo courtesy of the University of Michigan).
Cardiac disease researchers working with a mouse model of atherosclerosis have found that that a specific membrane bound enzyme has the potential to inhibit build-up of plaque and reduce risk of heart attack or stroke.

Investigators at the University of Michigan (Ann Arbor, USA) worked with the apolipoprotein E-deficient (ApoE-deficient) mouse model of atherosclerosis to examine the role of the enzyme CD39 (ectonucleotide tri(di)phosphohydrolase-1 or ENTPD1) in the process of plaque formation. This enzyme metabolizes locally released, intravascular ATP and ADP, thereby eliminating these pro-thrombotic and pro-inflammatory signaling molecules.

The investigators reported in the June 29, 2015, online edition of the Journal of Clinical Investigation that when animals fed a high-fat diet were compared, it was seen that ApoE-deficient mice that also lacked CD39 had a plaque burden that was markedly increased along with circulating markers of platelet activation. CD39 was prominently expressed in stable blood flow regions and was diminished in areas subjected to disturbed flow. Thus, CD39 activation followed the pattern of plaque formation.

In mice, disturbed blood flow as the result of partial carotid artery ligation rapidly suppressed endothelial CD39 expression. Moreover, unidirectional laminar shear stress induced protective CD39 expression in human endothelial cells.

“Better lifestyles and improved treatments have slowed the rates of death from atherosclerosis, but if CD39 proves to be as critical a factor in humans as in mice, it would be a major step forward in understanding heart disease,” said senior author Dr. David Pinsky, professor of cardiology at the University of Michigan.

Related Links:

University of Michigan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Platelet Function Analyzer
PL-12
New
Drug Testing Assays
Atellica DT 250 Analyzer

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more